造血细胞移植及其他细胞治疗后内皮损伤综合征的遗传易感性：攀登陡坡

Hematopoietic stem cell transplantation (HSCT) remains a cornerstone in the management of patients with hematological malignancies. Endothelial injury syndromes, such as HSCT-associated thrombotic microangiopathy (HSCT-TMA), veno-occlusive disease/sinusoidal obstruction syndrome (SOS/VOD), and capillary leak syndrome (CLS), constitute complications after HSCT.

Moreover, endothelial damage is prevalent after immunotherapy with chimeric antigen receptor-T (CAR-T) and can be manifested with cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).

Our literature review aims to investigate the genetic susceptibility in endothelial injury syndromes after HSCT and CAR-T cell therapy. Variations in complement pathway- and endothelial function-related genes have been associated with the development of HSCT-TMA. In these genes, CFHR5 , CFHR1 , CFHR3 , CFI , ADAMTS13 , CFB , C3 , C4 , C5 , and MASP1 are included.

Thus, patients with these variations might have a predisposition to complement activation, which is also exaggerated by other factors (such as acute graft-versus-host disease, infections, and calcineurin inhibitors). Few studies have examined the genetic susceptibility to SOS/VOD syndrome, and the implicated genes include CFH, methylenetetrahydrofolate reductase , and heparinase .

Finally, specific mutations have been associated with the onset of CRS ( PFKFB4 , CX3CR1 ) and ICANS ( PPM1D , DNMT3A , TE2 , ASXL1 ). More research is essential in this field to achieve better outcomes for our patients.